MedTrace Logo

Transition to KPL-387 Monotherapy Dosing & Administration Study

NCT07288216 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2026-05-20

No results posted yet for this study

Summary

The primary objective of this study is to characterize the efficacy and safety of dosing regimens used to transition from prior pericarditis therapies to KPL-387 monotherapy in participants with well-controlled recurrent pericarditis on standard therapies.

Conditions

  • Recurrent Pericarditis
  • Heart Diseases
  • Pericarditis

Interventions

DRUG

KPL-387

administered by subcutaneous injection

Sponsors & Collaborators

  • Kiniksa Pharmaceuticals, GmbH

    collaborator INDUSTRY

  • Kiniksa Pharmaceuticals International, plc

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-25
Primary Completion
2027-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Greece
  • Italy
  • Poland
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07288216 on ClinicalTrials.gov